Evelo Biosciences

Evelo Biosciences is a clinical-stage biotechnology company developing oral product candidates designed to act on the small intestine axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in regulating immunity, metabolism, and the nervous system. The company’s first candidate is a monoclonal microbial drug formulation selected for its potential to deliver defined pharmacological properties. Evelo’s therapies have the potential to become effective, safe, and affordable medicines to improve the lives of patients with inflammatory diseases and cancer.